THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Amgen is launching its recently approved Aranesp (darbepoetin alfa) prefilled SureClick autoinjector for patients with anemia associated with CKD and chemotherapy-induced anemia. The autoinjector’s ...
DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...
THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...
BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback